Reid Landes
Concepts (379)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Research Design | 5 | 2024 | 368 | 1.410 |
Why?
| | Parkinson Disease | 4 | 2025 | 168 | 1.170 |
Why?
| | Radiation-Protective Agents | 4 | 2021 | 69 | 1.160 |
Why?
| | Gait Disorders, Neurologic | 4 | 2025 | 37 | 1.150 |
Why?
| | Sample Size | 3 | 2023 | 50 | 1.050 |
Why?
| | Random Allocation | 2 | 2024 | 286 | 0.960 |
Why?
| | Reward | 10 | 2013 | 117 | 0.850 |
Why?
| | Smoking | 8 | 2015 | 514 | 0.820 |
Why?
| | Radiation Injuries | 2 | 2023 | 114 | 0.810 |
Why?
| | Antipsychotic Agents | 4 | 2014 | 234 | 0.790 |
Why?
| | Impulsive Behavior | 9 | 2015 | 76 | 0.760 |
Why?
| | Opioid-Related Disorders | 6 | 2023 | 404 | 0.720 |
Why?
| | Heart Diseases | 1 | 2023 | 217 | 0.680 |
Why?
| | Heart | 7 | 2023 | 352 | 0.670 |
Why?
| | Models, Psychological | 3 | 2017 | 78 | 0.620 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 161 | 0.600 |
Why?
| | Oxygen | 5 | 2023 | 332 | 0.600 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 461 | 0.590 |
Why?
| | Toxicology | 1 | 2018 | 27 | 0.580 |
Why?
| | Humans | 64 | 2025 | 52441 | 0.560 |
Why?
| | Tobacco Use Disorder | 7 | 2015 | 171 | 0.560 |
Why?
| | Data Interpretation, Statistical | 4 | 2024 | 166 | 0.550 |
Why?
| | Animals | 24 | 2025 | 13485 | 0.550 |
Why?
| | Male | 55 | 2025 | 26874 | 0.510 |
Why?
| | Protons | 3 | 2023 | 74 | 0.490 |
Why?
| | Radiation Protection | 2 | 2013 | 46 | 0.480 |
Why?
| | Levodopa | 3 | 2025 | 47 | 0.460 |
Why?
| | Housing, Animal | 2 | 2025 | 18 | 0.450 |
Why?
| | Confidence Intervals | 3 | 2013 | 158 | 0.450 |
Why?
| | Social Behavior | 2 | 2012 | 74 | 0.450 |
Why?
| | Female | 49 | 2025 | 28277 | 0.440 |
Why?
| | Heart Defects, Congenital | 1 | 2020 | 615 | 0.440 |
Why?
| | Gait | 3 | 2025 | 88 | 0.440 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2012 | 141 | 0.430 |
Why?
| | Amphetamine-Related Disorders | 2 | 2012 | 93 | 0.430 |
Why?
| | Methamphetamine | 3 | 2012 | 189 | 0.430 |
Why?
| | Animal Welfare | 1 | 2013 | 7 | 0.420 |
Why?
| | Psychotic Disorders | 2 | 2014 | 139 | 0.400 |
Why?
| | Motivation | 6 | 2019 | 283 | 0.400 |
Why?
| | Guidelines as Topic | 1 | 2013 | 111 | 0.400 |
Why?
| | Cognition Disorders | 5 | 2015 | 213 | 0.390 |
Why?
| | Evidence-Based Practice | 1 | 2013 | 108 | 0.390 |
Why?
| | Smoking Cessation | 6 | 2015 | 316 | 0.380 |
Why?
| | Cosmic Radiation | 2 | 2023 | 42 | 0.370 |
Why?
| | Adult | 27 | 2024 | 14205 | 0.370 |
Why?
| | Intestine, Small | 3 | 2021 | 112 | 0.360 |
Why?
| | Proportional Hazards Models | 2 | 2014 | 446 | 0.360 |
Why?
| | Behavior, Addictive | 2 | 2011 | 60 | 0.360 |
Why?
| | Quality Improvement | 1 | 2013 | 226 | 0.350 |
Why?
| | Radiation Injuries, Experimental | 1 | 2012 | 80 | 0.350 |
Why?
| | Radiation, Ionizing | 4 | 2021 | 96 | 0.350 |
Why?
| | Herbicide Resistance | 1 | 2011 | 2 | 0.350 |
Why?
| | Shikimic Acid | 1 | 2011 | 4 | 0.350 |
Why?
| | Crops, Agricultural | 1 | 2011 | 7 | 0.350 |
Why?
| | Spectrophotometry | 1 | 2011 | 27 | 0.350 |
Why?
| | Lethal Dose 50 | 3 | 2018 | 11 | 0.350 |
Why?
| | Probability | 4 | 2018 | 171 | 0.350 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2012 | 168 | 0.340 |
Why?
| | Buprenorphine | 4 | 2023 | 155 | 0.340 |
Why?
| | Glycine | 1 | 2011 | 78 | 0.330 |
Why?
| | Survival Analysis | 1 | 2012 | 656 | 0.330 |
Why?
| | Individuality | 1 | 2010 | 29 | 0.320 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 333 | 0.310 |
Why?
| | Cognition | 5 | 2019 | 363 | 0.310 |
Why?
| | Psychometrics | 2 | 2010 | 238 | 0.310 |
Why?
| | Computer Simulation | 3 | 2020 | 285 | 0.310 |
Why?
| | Central Nervous System Stimulants | 3 | 2008 | 198 | 0.300 |
Why?
| | Choice Behavior | 5 | 2013 | 82 | 0.300 |
Why?
| | Metabolic Diseases | 2 | 2023 | 48 | 0.300 |
Why?
| | Time Factors | 11 | 2017 | 2987 | 0.290 |
Why?
| | Dementia | 4 | 2014 | 168 | 0.290 |
Why?
| | Satiation | 1 | 2008 | 9 | 0.290 |
Why?
| | Plant Extracts | 1 | 2011 | 199 | 0.290 |
Why?
| | Middle Aged | 25 | 2025 | 13133 | 0.290 |
Why?
| | Young Adult | 11 | 2023 | 4346 | 0.280 |
Why?
| | Nicotine | 2 | 2009 | 174 | 0.280 |
Why?
| | Nuclear Weapons | 2 | 2019 | 4 | 0.270 |
Why?
| | Mice | 14 | 2025 | 5899 | 0.270 |
Why?
| | Quality Assurance, Health Care | 1 | 2008 | 147 | 0.270 |
Why?
| | Executive Function | 3 | 2015 | 85 | 0.270 |
Why?
| | Time Perception | 3 | 2017 | 28 | 0.260 |
Why?
| | Health Behavior | 2 | 2020 | 256 | 0.260 |
Why?
| | Mice, Inbred C57BL | 10 | 2025 | 1888 | 0.260 |
Why?
| | Guideline Adherence | 1 | 2008 | 142 | 0.260 |
Why?
| | Schizophrenia | 1 | 2008 | 257 | 0.250 |
Why?
| | DNA Methylation | 3 | 2022 | 573 | 0.250 |
Why?
| | Dose-Response Relationship, Radiation | 5 | 2023 | 185 | 0.250 |
Why?
| | Adipose Tissue | 2 | 2025 | 205 | 0.230 |
Why?
| | Quality of Life | 2 | 2022 | 893 | 0.230 |
Why?
| | Cocaine-Related Disorders | 3 | 2014 | 206 | 0.230 |
Why?
| | Decision Making | 5 | 2015 | 273 | 0.230 |
Why?
| | Aged | 19 | 2025 | 10242 | 0.230 |
Why?
| | Antiparkinson Agents | 1 | 2025 | 26 | 0.230 |
Why?
| | Adipose Tissue, Brown | 1 | 2025 | 45 | 0.220 |
Why?
| | Animals, Laboratory | 1 | 2024 | 6 | 0.220 |
Why?
| | Exercise | 3 | 2023 | 559 | 0.220 |
Why?
| | Rats | 6 | 2023 | 3228 | 0.220 |
Why?
| | Opiate Substitution Treatment | 3 | 2023 | 107 | 0.220 |
Why?
| | Temperature | 1 | 2025 | 166 | 0.220 |
Why?
| | Disease Progression | 2 | 2024 | 870 | 0.220 |
Why?
| | Writing | 1 | 2024 | 46 | 0.210 |
Why?
| | Biological Factors | 1 | 2023 | 11 | 0.210 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2020 | 504 | 0.200 |
Why?
| | Anti-Asthmatic Agents | 1 | 2023 | 33 | 0.200 |
Why?
| | Radiation Dosage | 4 | 2021 | 160 | 0.200 |
Why?
| | Tai Ji | 1 | 2023 | 22 | 0.200 |
Why?
| | Heart Atria | 1 | 2023 | 62 | 0.200 |
Why?
| | Energy Metabolism | 1 | 2025 | 315 | 0.190 |
Why?
| | Feasibility Studies | 2 | 2023 | 404 | 0.190 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 609 | 0.190 |
Why?
| | Transcranial Magnetic Stimulation | 2 | 2013 | 72 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2018 | 1365 | 0.190 |
Why?
| | Space Flight | 2 | 2019 | 32 | 0.190 |
Why?
| | Metformin | 1 | 2023 | 82 | 0.190 |
Why?
| | Models, Statistical | 3 | 2013 | 230 | 0.190 |
Why?
| | Spleen | 2 | 2020 | 166 | 0.180 |
Why?
| | Severity of Illness Index | 2 | 2024 | 1045 | 0.180 |
Why?
| | Lymphocytes | 1 | 2022 | 146 | 0.180 |
Why?
| | Reproducibility of Results | 2 | 2023 | 1223 | 0.180 |
Why?
| | Duodenum | 1 | 2021 | 34 | 0.180 |
Why?
| | Protein C | 1 | 2021 | 20 | 0.180 |
Why?
| | Social Class | 2 | 2012 | 97 | 0.180 |
Why?
| | Biomedical Research | 1 | 2024 | 260 | 0.180 |
Why?
| | Ions | 4 | 2023 | 31 | 0.180 |
Why?
| | Jejunum | 1 | 2021 | 54 | 0.170 |
Why?
| | Universities | 2 | 2024 | 174 | 0.170 |
Why?
| | Ileum | 1 | 2021 | 87 | 0.170 |
Why?
| | Odds Ratio | 3 | 2018 | 563 | 0.170 |
Why?
| | Hospitals, Veterans | 2 | 2013 | 107 | 0.170 |
Why?
| | Bayes Theorem | 2 | 2018 | 122 | 0.170 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 295 | 0.170 |
Why?
| | Survivors | 2 | 2019 | 121 | 0.170 |
Why?
| | Weightlessness Simulation | 1 | 2020 | 22 | 0.170 |
Why?
| | Thymus Gland | 1 | 2020 | 40 | 0.170 |
Why?
| | Gamma Rays | 1 | 2020 | 48 | 0.160 |
Why?
| | Amitriptyline | 1 | 2020 | 13 | 0.160 |
Why?
| | Home Care Agencies | 1 | 2020 | 6 | 0.160 |
Why?
| | Insulin Resistance | 1 | 2022 | 281 | 0.160 |
Why?
| | Aorta, Abdominal | 1 | 2020 | 39 | 0.160 |
Why?
| | Fibromyalgia | 1 | 2020 | 16 | 0.160 |
Why?
| | Psychological Tests | 2 | 2017 | 50 | 0.160 |
Why?
| | Adolescent | 10 | 2023 | 6713 | 0.160 |
Why?
| | Aged, 80 and over | 11 | 2019 | 3449 | 0.160 |
Why?
| | Healthcare Disparities | 2 | 2014 | 291 | 0.160 |
Why?
| | Monte Carlo Method | 1 | 2020 | 89 | 0.160 |
Why?
| | Quality Indicators, Health Care | 1 | 2020 | 91 | 0.150 |
Why?
| | Asthma | 1 | 2023 | 313 | 0.150 |
Why?
| | Phenotype | 1 | 2022 | 792 | 0.150 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 227 | 0.150 |
Why?
| | Oxygen Radioisotopes | 1 | 2019 | 14 | 0.150 |
Why?
| | Arkansas | 8 | 2022 | 2013 | 0.150 |
Why?
| | Home Care Services | 1 | 2020 | 70 | 0.150 |
Why?
| | Thigh | 1 | 2018 | 34 | 0.150 |
Why?
| | Analysis of Variance | 2 | 2017 | 558 | 0.140 |
Why?
| | User-Computer Interface | 1 | 2018 | 78 | 0.140 |
Why?
| | Weight Gain | 2 | 2022 | 235 | 0.140 |
Why?
| | Skin | 1 | 2021 | 416 | 0.140 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 493 | 0.140 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2018 | 96 | 0.140 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2017 | 38 | 0.130 |
Why?
| | Gene Expression | 2 | 2019 | 618 | 0.130 |
Why?
| | Intention | 1 | 2017 | 48 | 0.130 |
Why?
| | Drug Monitoring | 2 | 2014 | 81 | 0.130 |
Why?
| | Whole-Body Irradiation | 2 | 2021 | 128 | 0.130 |
Why?
| | Directive Counseling | 2 | 2014 | 23 | 0.130 |
Why?
| | Telephone | 2 | 2014 | 70 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 2 | 2019 | 1140 | 0.130 |
Why?
| | United States | 5 | 2020 | 5215 | 0.130 |
Why?
| | Depressive Disorder | 2 | 2009 | 335 | 0.120 |
Why?
| | Myocardium | 1 | 2019 | 471 | 0.120 |
Why?
| | Body Weight | 2 | 2020 | 524 | 0.120 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2015 | 21 | 0.120 |
Why?
| | Hematopoietic Stem Cells | 1 | 2017 | 180 | 0.120 |
Why?
| | Gene Duplication | 1 | 2015 | 16 | 0.120 |
Why?
| | Green Fluorescent Proteins | 1 | 2015 | 85 | 0.120 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2015 | 37 | 0.110 |
Why?
| | Students | 1 | 2017 | 230 | 0.110 |
Why?
| | Liver | 3 | 2023 | 1150 | 0.110 |
Why?
| | Conditioning, Operant | 1 | 2015 | 105 | 0.110 |
Why?
| | Hyperlipidemias | 1 | 2014 | 52 | 0.110 |
Why?
| | Educational Status | 4 | 2015 | 227 | 0.110 |
Why?
| | Hyperglycemia | 1 | 2014 | 88 | 0.110 |
Why?
| | Alzheimer Disease | 2 | 2009 | 356 | 0.100 |
Why?
| | Biofeedback, Psychology | 1 | 2013 | 18 | 0.100 |
Why?
| | Electric Stimulation | 1 | 2013 | 115 | 0.100 |
Why?
| | Medical Records | 1 | 2013 | 83 | 0.100 |
Why?
| | Databases, Factual | 2 | 2013 | 721 | 0.100 |
Why?
| | Sexual Behavior | 1 | 2014 | 127 | 0.100 |
Why?
| | Pain | 2 | 2023 | 373 | 0.100 |
Why?
| | Cluster Analysis | 1 | 2013 | 236 | 0.100 |
Why?
| | Eye Diseases | 1 | 2013 | 33 | 0.100 |
Why?
| | Physicians, Primary Care | 1 | 2013 | 43 | 0.100 |
Why?
| | Cross-Sectional Studies | 4 | 2024 | 1677 | 0.100 |
Why?
| | Cholesterol, LDL | 1 | 2013 | 42 | 0.100 |
Why?
| | Japan | 3 | 2019 | 40 | 0.100 |
Why?
| | Diabetes Complications | 1 | 2013 | 124 | 0.100 |
Why?
| | Sex Characteristics | 1 | 2014 | 210 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2024 | 756 | 0.090 |
Why?
| | Animal Experimentation | 1 | 2012 | 3 | 0.090 |
Why?
| | Internet | 1 | 2014 | 262 | 0.090 |
Why?
| | Internal-External Control | 1 | 2012 | 31 | 0.090 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2014 | 324 | 0.090 |
Why?
| | Aggression | 2 | 2011 | 51 | 0.090 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 199 | 0.090 |
Why?
| | Community Networks | 1 | 2012 | 51 | 0.090 |
Why?
| | Commodification | 1 | 2011 | 2 | 0.090 |
Why?
| | Treatment Outcome | 7 | 2018 | 5508 | 0.090 |
Why?
| | Veterans | 2 | 2018 | 573 | 0.090 |
Why?
| | Herbicides | 1 | 2011 | 11 | 0.090 |
Why?
| | Qualitative Research | 1 | 2013 | 365 | 0.090 |
Why?
| | Receptors, Steroid | 1 | 2010 | 20 | 0.080 |
Why?
| | Adolescent Behavior | 1 | 2011 | 107 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 485 | 0.080 |
Why?
| | Psychomotor Agitation | 1 | 2011 | 50 | 0.080 |
Why?
| | Education | 1 | 2010 | 39 | 0.080 |
Why?
| | Antibodies, Monoclonal | 2 | 2005 | 475 | 0.080 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2010 | 78 | 0.080 |
Why?
| | Clinical Competence | 1 | 2013 | 405 | 0.080 |
Why?
| | Dexamethasone | 2 | 2010 | 434 | 0.080 |
Why?
| | Meta-Analysis as Topic | 1 | 2010 | 39 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 358 | 0.080 |
Why?
| | Blood Glucose | 1 | 2013 | 483 | 0.080 |
Why?
| | Memory, Short-Term | 1 | 2010 | 77 | 0.080 |
Why?
| | Aging | 1 | 2015 | 722 | 0.080 |
Why?
| | Marijuana Abuse | 1 | 2011 | 153 | 0.080 |
Why?
| | Mutation | 1 | 2015 | 1331 | 0.080 |
Why?
| | Extinction, Psychological | 1 | 2009 | 34 | 0.080 |
Why?
| | Logistic Models | 4 | 2014 | 930 | 0.080 |
Why?
| | Apolipoprotein E4 | 1 | 2009 | 24 | 0.080 |
Why?
| | Ophthalmic Solutions | 1 | 2009 | 19 | 0.080 |
Why?
| | Diphenhydramine | 1 | 2009 | 19 | 0.080 |
Why?
| | Anesthesia, Local | 1 | 2009 | 18 | 0.080 |
Why?
| | Soybean Proteins | 1 | 2010 | 168 | 0.070 |
Why?
| | Cornea | 1 | 2009 | 53 | 0.070 |
Why?
| | Epigenesis, Genetic | 2 | 2022 | 396 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2017 | 601 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 465 | 0.070 |
Why?
| | Anesthetics, Local | 1 | 2009 | 77 | 0.070 |
Why?
| | Health Care Surveys | 1 | 2008 | 177 | 0.070 |
Why?
| | Models, Biological | 1 | 2011 | 735 | 0.070 |
Why?
| | Analgesics, Opioid | 3 | 2023 | 601 | 0.070 |
Why?
| | Child | 4 | 2023 | 7194 | 0.070 |
Why?
| | Analgesics | 1 | 2008 | 106 | 0.060 |
Why?
| | Rabbits | 2 | 2023 | 370 | 0.060 |
Why?
| | Mental Competency | 1 | 2007 | 32 | 0.060 |
Why?
| | Sex Factors | 3 | 2015 | 735 | 0.060 |
Why?
| | Informed Consent | 1 | 2007 | 92 | 0.060 |
Why?
| | Antibody Affinity | 1 | 2005 | 9 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 498 | 0.060 |
Why?
| | Thermogenesis | 1 | 2025 | 31 | 0.060 |
Why?
| | Faculty | 1 | 2024 | 72 | 0.050 |
Why?
| | Activities of Daily Living | 2 | 2020 | 185 | 0.050 |
Why?
| | Neuropsychological Tests | 3 | 2011 | 346 | 0.050 |
Why?
| | Research Personnel | 1 | 2024 | 71 | 0.050 |
Why?
| | Mental Disorders | 1 | 2008 | 427 | 0.050 |
Why?
| | Single-Blind Method | 2 | 2013 | 118 | 0.050 |
Why?
| | Program Evaluation | 1 | 2024 | 351 | 0.050 |
Why?
| | Prefrontal Cortex | 2 | 2013 | 85 | 0.050 |
Why?
| | Token Economy | 2 | 2014 | 33 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 116 | 0.050 |
Why?
| | Cytogenetic Analysis | 1 | 2022 | 79 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2014 | 641 | 0.050 |
Why?
| | Alendronate | 1 | 2002 | 24 | 0.050 |
Why?
| | Methadone | 1 | 2023 | 184 | 0.050 |
Why?
| | Risk Factors | 3 | 2019 | 3971 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 122 | 0.050 |
Why?
| | Primates | 1 | 2021 | 22 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2021 | 94 | 0.040 |
Why?
| | Chromans | 1 | 2021 | 34 | 0.040 |
Why?
| | Immunoblotting | 1 | 2021 | 118 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 230 | 0.040 |
Why?
| | Vitamin E | 1 | 2021 | 77 | 0.040 |
Why?
| | Catecholamines | 1 | 2020 | 44 | 0.040 |
Why?
| | Drinking | 1 | 2020 | 42 | 0.040 |
Why?
| | Interviews as Topic | 2 | 2012 | 270 | 0.040 |
Why?
| | Rats, Long-Evans | 1 | 2020 | 23 | 0.040 |
Why?
| | Intestines | 1 | 2021 | 159 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 228 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2002 | 234 | 0.040 |
Why?
| | Policy | 1 | 2020 | 27 | 0.040 |
Why?
| | Area Under Curve | 2 | 2015 | 182 | 0.040 |
Why?
| | Insulin | 1 | 2022 | 485 | 0.040 |
Why?
| | Genotype | 1 | 2021 | 563 | 0.040 |
Why?
| | Age Factors | 2 | 2015 | 1120 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2020 | 6694 | 0.040 |
Why?
| | Heart Rate | 1 | 2021 | 311 | 0.040 |
Why?
| | Energy Intake | 1 | 2020 | 183 | 0.040 |
Why?
| | Centromere | 1 | 2019 | 12 | 0.040 |
Why?
| | DNA, Satellite | 1 | 2019 | 13 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2020 | 183 | 0.040 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2019 | 86 | 0.040 |
Why?
| | Osteoclasts | 1 | 2002 | 423 | 0.040 |
Why?
| | Carbon | 1 | 2019 | 60 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 89 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 3 | 2010 | 1558 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2021 | 977 | 0.040 |
Why?
| | Organ Size | 1 | 2018 | 226 | 0.040 |
Why?
| | Methionine | 1 | 2019 | 142 | 0.040 |
Why?
| | Pregnancy | 1 | 2025 | 2642 | 0.030 |
Why?
| | Medicare | 1 | 2020 | 281 | 0.030 |
Why?
| | Psychological Theory | 1 | 2017 | 26 | 0.030 |
Why?
| | Resistance Training | 1 | 2018 | 102 | 0.030 |
Why?
| | Retroelements | 1 | 2017 | 13 | 0.030 |
Why?
| | Emotions | 1 | 2019 | 172 | 0.030 |
Why?
| | Mice, Inbred CBA | 1 | 2017 | 37 | 0.030 |
Why?
| | Apoptosis | 2 | 2019 | 1120 | 0.030 |
Why?
| | Hematopoiesis | 1 | 2017 | 69 | 0.030 |
Why?
| | Species Specificity | 1 | 2017 | 194 | 0.030 |
Why?
| | Gene Knock-In Techniques | 1 | 2015 | 22 | 0.030 |
Why?
| | Genes | 1 | 2015 | 32 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 298 | 0.030 |
Why?
| | Age Distribution | 1 | 2015 | 176 | 0.030 |
Why?
| | Pancreas | 1 | 2015 | 71 | 0.030 |
Why?
| | Exons | 1 | 2015 | 101 | 0.030 |
Why?
| | Rural Population | 1 | 2020 | 587 | 0.030 |
Why?
| | Bone and Bones | 1 | 2018 | 492 | 0.030 |
Why?
| | Antibody Specificity | 2 | 2005 | 36 | 0.030 |
Why?
| | Infant | 1 | 2023 | 3709 | 0.030 |
Why?
| | Risk Assessment | 1 | 2019 | 1349 | 0.030 |
Why?
| | Control Groups | 1 | 2013 | 9 | 0.030 |
Why?
| | Obesity | 1 | 2022 | 1176 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2005 | 304 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2014 | 159 | 0.030 |
Why?
| | Tobacco Products | 1 | 2015 | 126 | 0.020 |
Why?
| | Narcotic Antagonists | 1 | 2014 | 150 | 0.020 |
Why?
| | Gambling | 1 | 2013 | 18 | 0.020 |
Why?
| | Motor Activity | 2 | 2005 | 227 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2018 | 799 | 0.020 |
Why?
| | United States Department of Veterans Affairs | 1 | 2014 | 291 | 0.020 |
Why?
| | Ophthalmology | 1 | 2013 | 34 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 292 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 1004 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 680 | 0.020 |
Why?
| | Behavior Therapy | 1 | 2013 | 181 | 0.020 |
Why?
| | Health Status Disparities | 1 | 2014 | 218 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2013 | 288 | 0.020 |
Why?
| | Videotape Recording | 1 | 2011 | 26 | 0.020 |
Why?
| | Verbal Behavior | 1 | 2011 | 36 | 0.020 |
Why?
| | Homes for the Aged | 1 | 2011 | 33 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2010 | 78 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2010 | 48 | 0.020 |
Why?
| | Midazolam | 1 | 2010 | 37 | 0.020 |
Why?
| | Noise | 1 | 2011 | 42 | 0.020 |
Why?
| | Response Elements | 1 | 2010 | 29 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 138 | 0.020 |
Why?
| | Caseins | 1 | 2010 | 78 | 0.020 |
Why?
| | Substance Abuse Detection | 1 | 2010 | 93 | 0.020 |
Why?
| | Protein Transport | 1 | 2010 | 172 | 0.020 |
Why?
| | Income | 1 | 2010 | 106 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2015 | 2294 | 0.020 |
Why?
| | Nursing Homes | 1 | 2011 | 111 | 0.020 |
Why?
| | Language | 1 | 2011 | 142 | 0.020 |
Why?
| | Nicotinic Agonists | 1 | 2009 | 54 | 0.020 |
Why?
| | Self Administration | 1 | 2009 | 90 | 0.020 |
Why?
| | Administration, Topical | 1 | 2009 | 62 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2009 | 85 | 0.020 |
Why?
| | Reaction Time | 1 | 2009 | 209 | 0.020 |
Why?
| | Regression Analysis | 1 | 2009 | 400 | 0.020 |
Why?
| | Self Concept | 1 | 2008 | 63 | 0.020 |
Why?
| | Internship and Residency | 1 | 2013 | 438 | 0.020 |
Why?
| | Patient Compliance | 1 | 2009 | 228 | 0.020 |
Why?
| | Audiovisual Aids | 1 | 2007 | 13 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2010 | 1134 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 938 | 0.020 |
Why?
| | Reading | 1 | 2007 | 76 | 0.020 |
Why?
| | Prevalence | 1 | 2009 | 1016 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 2005 | 193 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2005 | 190 | 0.010 |
Why?
| | Drug Overdose | 1 | 2005 | 161 | 0.010 |
Why?
| | Amphetamine | 1 | 2003 | 36 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2003 | 175 | 0.010 |
Why?
| | Prednisolone | 1 | 2002 | 56 | 0.010 |
Why?
| | Osteoporosis | 1 | 2002 | 157 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2005 | 1483 | 0.010 |
Why?
| | Cell Survival | 1 | 2002 | 598 | 0.010 |
Why?
| | Bone Density | 1 | 2002 | 396 | 0.010 |
Why?
| | Bone Resorption | 1 | 2002 | 300 | 0.010 |
Why?
| | Osteoblasts | 1 | 2002 | 478 | 0.010 |
Why?
| | Brain | 1 | 2003 | 1337 | 0.010 |
Why?
|
|
Landes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|